Tirbanibulin Production Cost Reports

The report provides detailed analysis essential for establishing a tirbanibulin production plant. It encompasses all critical aspects necessary for tirbanibulin production, including the cost of tirbanibulin production, tirbanibulin plant cost, tirbanibulin production costs, and the overall tirbanibulin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a tirbanibulin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Tirbanibulin Market Analysis: Demand and Supply Analysis, and Sourcing

Tirbanibulin is a synthetic small-molecule drug that inhibits tubulin polymerization, disrupts Src kinase signaling, and blocks the growth of rapidly dividing skin cells. It causes dividing cells to stop in the G2/M phase, increases p53 levels, and activates caspase-3, leading to cell death. Athenex, through its Kinex unit, developed tirbanibulin under the code KX2-391. US regulators approved it as Klisyri 1 percent ointment early this decade for the treatment of actinic keratosis of the face or scalp. EU approval followed about seven months later. The treatment is short, simple, and self-administered, with one packet applied each day for five days.

Tirbanibulin volumes are very small. Demand mainly comes from the treatment of actinic keratosis, a common precancerous skin condition caused by sun damage. Actinic keratosis affects an estimated 11 to 25 percent of Americans, and some lesions can progress to squamous cell carcinoma. Dermatologists treat entire areas of sun-damaged skin rather than only visible lesions because hidden lesions, new lesions, and recurrences are common. Later, an FDA label update expanded the treatable area from 25 cm² to 100 cm² and introduced a new 350 mg packet alongside the original 250 mg packet. Almirall reported half-year Klisyri sales of €8.2 million in a recent period, representing a 28.1 percent increase. However, sales remain relatively small. Almirall markets the brand through its dermatology teams in the US and Europe.

Tirbanibulin supply is small, specialized, and closely linked to its brand owners. Almirall holds rights in the US and most of Europe, while Guangzhou Xiangxue Pharmaceutical holds licensed rights for China. After Athenex entered bankruptcy, the technical know-how for manufacturing tirbanibulin was licensed to Almirall, allowing it to source the product from a third-party supplier. Four active US DMFs are held by Moehs Iberica, Indena, Chongqing Sintaho Pharmaceutical, and Taro Pharmaceutical. Their filings indicate that generic developers, contract manufacturers, and second-source suppliers are already preparing for the product's next phase. Any tirbanibulin demand and supply analysis therefore needs to consider patient uptake, the larger treatment area, generic entry timing, and the very small API volume. Upon receipt, buyers typically check HPLC assay, related substances, residual palladium, residual solvents, ethyl chloride, and particle size.

Summary of the Product, Grades, and Uses

Tirbanibulin has the molecular formula C26H29N3O3 and a molar mass of 431.54 g/mol under CAS number 897016-82-9. Chemically, it is N-benzyl-2-[5-[4-[2-morpholin-4-ylethoxy]phenyl]pyridin-2-yl]acetamide. Its structure contains a pyridine ring, a phenyl ring, a morpholinoethoxy side chain, and a benzyl acetamide group. Since the molecule has no stereocenter, it does not require chiral purity controls, resolution steps, or enantiomer testing. Athenex's process patents describe both the free base and salts such as the mesylate and dihydrochloride.

Tirbanibulin API is supplied according to brand and DMF specifications rather than a pharmacopeia monograph. Athenex's process patent specifies purity above 98 percent by HPLC, palladium below 100 ppm, and ethyl chloride below 250 ppm. Residual ethanol, ethyl acetate, heptane, and anisole are also controlled, along with water, sulfated ash, and heavy metals. Ointment manufacturers require tight control of particle size, polymorph, and moisture to ensure that the drug spreads evenly at 1 percent strength. Reference standards, impurity standards, and labeled compounds make up a small analytical-grade segment supplied to QC laboratories, generic developers, and researchers.

Klisyri contains 10 mg of tirbanibulin per gram of ointment. Each single-use packet contains 250 mg or 350 mg of ointment, meaning that a five-day treatment course requires only milligrams of API.

Main End-Uses of Tirbanibulin

Actinic keratosis on the face and scalp takes essentially all tirbanibulin volume today. Dermatologists prescribe it as a field treatment for sun-damaged skin with multiple lesions on the forehead, cheeks, nose, or scalp. Five days of treatment is much shorter than many older topical regimens, which can run for weeks. Patients apply one packet daily to a set area, wash their hands, follow the label on washing, and stop after day five. Local skin reactions such as redness, flaking, crusting & swelling are usually mild and short-lived, which helps adherence.

Tirbanibulin competes with several established actinic keratosis treatments. Rivals include 5-fluorouracil cream, imiquimod cream, diclofenac gel, photodynamic therapy, and cryotherapy. Older topical creams often need weeks of use and cause more redness, crusting, pain, and patient dropout. Tirbanibulin's short course, simple dosing & better tolerability are its main selling points with dermatologists, patients, and payers. With the expanded 100 cm² label, dermatologists can treat a full forehead, balding scalp, or both cheeks in one course.

Research use forms the remaining outlet. Tirbanibulin was first studied as an oral cancer drug, including in prostate cancer and other solid tumors, because it targets tubulin and Src signaling. Researchers continue to study it in psoriasis, other skin conditions, and tumor models, alone or in combination. Guangzhou Xiangxue's China license covers actinic keratosis and other indications, with milestone, royalty, and sales-based payments tied to approval and launch. Research labs buy small amounts as a tubulin inhibitor reference compound.

Tirbanibulin Market Risks

Tirbanibulin sits in a niche dermatology market with strong low-cost competition, so pricing and uptake are the main commercial risks. Generic 5-fluorouracil and imiquimod are cheap and familiar to dermatologists. Insurers, pharmacy benefit managers, and national health systems may require patients to try generics first. Klisyri sales remain small compared with major dermatology brands, biologics, and newer topical drugs. Athenex's bankruptcy disrupted the original supply chain, royalty arrangements, and technical support. Generic entry will come once patents and exclusivity expire, and four DMF holders are already positioned to supply generic ointment makers, contract fillers, and hospital tenders in Europe.

Tirbanibulin manufacturing carries its own risks because the route uses palladium coupling, a strong base, and alkyl chloride reagents. Residual palladium must be cleared to low ppm levels with scavengers, carbon, or extra crystallizations. 4-[2-Chloroethyl]morpholine is a nitrogen mustard-type alkylating agent and a potential mutagenic impurity. Ethyl chloride can form when ethanol meets hydrochloric acid during workup or salt steps, so solvent choice, temperature, and drying must be controlled. Cyanomethylation uses a strong base and needs dry, cold, oxygen-free conditions. Most rejected lots trace back to related substances, palladium residue, particle size, or residual solvent failures.

Tirbanibulin Production Process and Main Cost Drivers

Tirbanibulin production is a five-step synthesis, from etherification through Suzuki coupling, cyanomethylation, methanolysis, amidation, and final purification.

1. By Etherification, Suzuki Coupling, and Benzylamide Formation: The main inputs are 4-bromophenol, 4-[2-chloroethyl]morpholine, 6-fluoropyridin-3-yl boronic acid, a palladium catalyst, acetonitrile, a strong base, methanol, an acid catalyst, benzylamine, process solvents & purification media.

Tirbanibulin synthesis starts by alkylating 4-bromophenol with 4-[2-chloroethyl]morpholine in the presence of a base. That reaction gives 4-[2-[4-bromophenoxy]ethyl]morpholine, which is then joined to 6-fluoropyridin-3-yl boronic acid by Suzuki coupling. Tetrakis-triphenylphosphine palladium is the catalyst named in the Athenex process patent, used with a base, an aqueous organic solvent mix & heating. After coupling, the product is a 2-fluoropyridine carrying the morpholinoethoxy phenyl group, ready for side-chain building.

Next, the fluorine is displaced by the anion of acetonitrile, which gives a pyridin-2-yl acetonitrile. Forming the acetonitrile anion needs a strong base, dry solvent, nitrogen cover, and careful cooling. Acid-catalyzed methanolysis then converts the nitrile to the methyl ester, the last intermediate before the amide.

To finish, the methyl ester reacts with benzylamine to form the N-benzyl acetamide, which is tirbanibulin. The crude product is purified by crystallization, carbon treatment, and palladium scavenging where needed. Makers can isolate the free base directly or convert it to a salt, though the ointment uses the drug substance specified by the brand owner. The final API is dried, milled, sieved, and packed in double polyethylene bags inside sealed drums. QC covers assay, related substances, palladium, residual solvents, ethyl chloride, water, and particle size. Cost is driven by boronic acid and palladium cost, nitrile step yield, purification losses & GMP overhead.

Main Factors Affecting Tirbanibulin Production Cost

Tirbanibulin production cost is shaped first by the tiny scale of demand. Each five-day course uses only about 12.5 to 17.5 mg of tirbanibulin, based on five packets of 250 or 350 mg at 1 percent. World API demand is therefore measured in kilograms a year, not tonnes, even with tens of thousands of patients treated. Scale drives everything here. Fixed costs for validation, QC, regulatory filings, stability programs, and batch documentation dominate. One campaign may cover a full year of demand, so most of the year the equipment runs other products.

Raw material and catalyst costs come next. 6-Fluoropyridin-3-yl boronic acid is a specialty building block with a high price per kilogram. Palladium catalyst, ligand, and scavengers add cost to the coupling step, partly offset by metal recovery credits. 4-[2-Chloroethyl]morpholine, 4-bromophenol, benzylamine & acetonitrile are cheaper commodity reagents. At this scale, raw material cost is often smaller than labor, testing, documentation & equipment cleaning costs.

Yield, purification, and compliance complete the picture. Cyanomethylation, methanolysis, and amidation decide overall yield. Each recrystallization trades yield for purity, color, and palladium removal. Mutagenic impurity control, palladium testing, method validation, and stability studies add analytical cost. DMF upkeep, buyer audits, and change control for a single-customer product add fixed overhead.

Raw Materials for Tirbanibulin Production Plant and its Procurement

Raw material sourcing for tirbanibulin centers on a few specialty building blocks. 6-Fluoropyridin-3-yl boronic acid comes from Chinese and Indian fine chemical makers. 4-[2-Chloroethyl]morpholine is usually sold as its hydrochloride salt by fine chemical suppliers. 4-Bromophenol, benzylamine & acetonitrile are widely available commodity chemicals from many suppliers in China, India, and Europe. Palladium catalysts come from precious metal catalyst suppliers that also take back spent metal. Bases, solvents, scavengers, and packaging complete the bill of materials.

Cheap building blocks are not always the cheapest route to on-spec tirbanibulin. Isomeric impurities in the fluoropyridine boronic acid carry through to hard-to-remove related substances. Boronic acid quality, water content, and boroxine content affect coupling yield and palladium use. Residual water in acetonitrile or solvents kills the strong base in the nitrile step. Impure benzylamine can form amide by-products.

Such sensitivities shape how a tirbanibulin plant buys and qualifies its inputs. Contracts specify assay, isomer content, water & heavy metals for each key material. Vendor qualification runs through audits, impurity-fate studies, and regulatory starting material justification. Incoming checks cover identity, assay by HPLC or GC, and water by Karl Fischer. Because volumes are tiny, many makers buy a full year of building blocks in one lot, test it once, and store it under controlled conditions. Dual sourcing for the boronic acid protects against supply gaps. Lead times can be long.

Sustainability and Regulatory Requirements

Tirbanibulin manufacture raises modest environmental concerns because volumes are very small. Key issues are palladium waste, halogenated organics, morpholine-bearing aqueous streams, and solvent use. Spent palladium, scavenger resins, and activated carbon from the coupling and purification steps are recovered or treated through catalyst suppliers. Solvents are recovered where practical or sent to licensed incineration. Batch waste volumes stay small. Aqueous waste carries morpholine derivatives, boron salts, and bromide that need treatment. Potent compound handling, including isolators, gowning, and air monitoring, protects operators from a cytotoxic tubulin inhibitor.

Regulatory obligations for tirbanibulin follow from its status as a prescription dermatology API. In the US, makers file a Type II DMF and work under FDA cGMP per 21 CFR 210/211. Generic ointment makers will need ANDAs, likely with complex bioequivalence approaches such as in vitro release, physicochemical sameness, or clinical endpoint studies for a topical product. In Europe, an ASMF supports the Klisyri or generic marketing authorization. ICH Q7 governs API manufacture, and ICH Q11 covers starting material choice. ICH M7 covers alkyl chloride reagents and ethyl chloride, ICH Q3D covers palladium, and ICH Q3C covers solvents.

CAPEX and OPEX for a Tirbanibulin Production Plant

Most tirbanibulin production happens in a small multipurpose API suite rather than a dedicated factory. Capital starts with small glass-lined and stainless steel reactors with inert gas, low-temperature cooling & vacuum. Cyanomethylation needs low-temperature capability, dry solvent handling, and inert gas. Downstream come filters, crystallizers, a vacuum dryer, a mill, and a sieve in a contained suite. Palladium scavenging columns or carbon treatment sit after the coupling step. Utilities cover steam, chilled brine, nitrogen, purified water, solvent recovery, and HVAC for potent compounds. On the QC side, a laboratory houses HPLC, GC headspace, ICP-MS, Karl Fischer titrators, and particle size analysis.

Tirbanibulin operating cost starts with QC, labor, and GMP overhead rather than raw materials. Building blocks, palladium, solvents, utilities, waste disposal, packaging & insured freight make up the rest. Cost per kilogram comes down to campaign size, coupling and nitrile yield, purification losses & analytical load. In practice, the tirbanibulin plant setup cost depends on whether the product runs on existing multipurpose equipment or needs new contained capacity. Most makers add it to a site that already runs other high-potency, oncology, or dermatology APIs, which shares containment, analytics & quality systems.

Plant Location and Investment Factors

Any workable tirbanibulin site is an existing GMP API plant with potent compound experience, strong analytics, and regulatory filing history. Spain, Italy & China already host API makers with tirbanibulin DMFs. Indian and Chinese sites offer lower labor, utility, and construction costs for future generic supply. European sites offer proximity to Almirall, EU regulators, and established ointment fillers. Strong analytical teams matter most, because testing, method validation, and stability work dominate cost.

For a tirbanibulin project, the first decision is whether to target the brand owner or future generics. Supplying Almirall means meeting its specifications, audits, and change-control rules under a long-term contract. Supplying generics means filing a DMF early and waiting for patent expiry. Backward integration is the second decision. Making the fluoropyridine boronic acid in-house cuts cost but adds steps to a very small product. Most makers instead buy building blocks and focus on the coupling, side-chain, amidation, and purification steps.

Major Tirbanibulin Producing Regions

Europe is the main producing region for tirbanibulin API today. Moehs Iberica in Spain and Indena in Italy both hold active US DMFs, and Indena's DMF has completed GDUFA review. China supplies through Chongqing Sintaho Pharmaceutical, which also holds a US DMF. Athenex once ran oncology API plants in Chongqing before selling that business to Chongqing Comfort Pharmaceutical. Taro Pharmaceutical holds a US DMF linked to its dermatology business. India is likely to add capacity as generic interest grows, given its strength in topical generics, oncology APIs, and US filings.

Key Tirbanibulin Producers

Almirall

• Barcelona-based dermatology company that holds Klisyri rights in the US and most of Europe.
• Licensed the manufacturing know-how after Athenex's bankruptcy to secure third-party supply.
• Gained FDA approval to expand treatment to 100 cm² with a new 350 mg packet.
• Reported strong double-digit Klisyri sales growth in recent results.

Moehs Group

• Barcelona-based API maker with an active US DMF for tirbanibulin.
• Produces niche and complex APIs for regulated generic and brand customers.
• Competes on EU manufacturing & broad regulatory filings.
• Supplies dermatology and oncology API customers worldwide.

Indena

• Milan-based API maker known for complex and plant-derived APIs.
• Holds a US DMF for tirbanibulin that has completed GDUFA review.
• Competes on high-potency handling, EU GMP & regulatory depth.
• Supplies brand and generic customers in the US and Europe.

Chongqing Sintaho Pharmaceutical

• Chongqing-based API maker with an active US DMF for tirbanibulin.
• Holds FDA, ISO 9001 & GMP documentation for its API supply.
• Competes on a Chinese cost base & oncology API experience.
• Supplies regulated and emerging markets.

Taro Pharmaceutical Industries

• Dermatology-focused generic drug maker with an active US DMF for tirbanibulin.
• Specializes in topical creams, ointments & gels.
• Competes on topical formulation know-how & US generic market reach.
• Positioned for future generic tirbanibulin ointment.

Guangzhou Xiangxue Pharmaceutical

• Chinese pharmaceutical company that licensed tirbanibulin ointment rights for China.
• Agreed to milestone payments of up to US$40 million and sales-based payments of up to US$30 million.
• Covers actinic keratosis and other indications in China.
• Competes on Chinese market access & dermatology distribution.